

**Centers for Disease Control and Prevention
Model Performance Evaluation Program
Human T-Lymphotropic Virus Types I and II
(HTLV-I/II) Testing**

**Figures Used to Summarize the
Candidate Reference Laboratory Results
for the October 6, 1997 Shipment**



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

Centers for Disease Control and Prevention

Public Health Practice Program Office

Division of Laboratory Systems

Atlanta, Georgia 30333



**Use of trade names is for identification only and does not constitute endorsement by the
Public Health Service or by the U.S. Department of Health and Human Services.**

Report of the October 6, 1997 Human T-lymphotropic virus types I and II (HTLV-I/II) Performance Evaluation Sample Testing Results Provided by Candidate Reference Laboratories in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC).

The production of this report was coordinated in CDC by:

Public Health Practice Program Office.....Edward L. Baker, M.D., M.P.H., Director
Division of Laboratory Systems.....Carlyn L. Collins, M.D., M.P.H., Director
Laboratory Practice Assessment Branch.....Thomas L. Hearn, Ph.D., Chief

The material in this report was developed and prepared by:

Model Performance Evaluation Program (MPEP).....William O. Schalla, M.S., Chief
MPEP HTLV Performance Evaluation.....Laurina O. Williams, Ph.D.,
HTLV Project Coordinator

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-8130 or (770) 488-8098.

**Centers for Disease Control and Prevention (CDC)
 Model Performance Evaluation Program
 Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Testing
 October 6, 1997 Candidate Reference Laboratory Shipment**

Table 1

Vial Label Number	CDC Donor Number	CDC Contractor Result ²	Laboratory Interpretation ¹			
			EIA		WB	IIF
			INIT. ³	FINAL ⁴		
01	06	Positive	—	—	—	—
02	08	Positive	—	—	—	—
03	11	Negative	—	—	—	—
04	15	Negative	—	—	—	—
05	03	Positive	—	—	—	—
06	05	Positive	—	—	—	—
07	09	Negative	—	—	—	—
08	07	Positive	—	—	—	—
09	12	Negative	—	—	—	—
10	13	Negative	—	—	—	—
11	02	Positive	—	—	—	—
12	16	Negative	—	—	—	—
13	10	Negative	—	—	—	—
14	04	Positive	—	—	—	—
15	01	Positive	—	—	—	—
16	14	Negative	—	—	—	—

¹ Laboratory Interpretation space (to be completed by candidate reference laboratory) provided to facilitate comparison of candidate reference laboratory result with CDC result.

² The CDC result was obtained by contractor after composite EIA, WB, and RIPA testing, and employing the interpretation criteria of the Public Health Service Working Group.


³ Initial EIA interpretation

⁴ Final EIA interpretation

SUPPLEMENTAL INFORMATION FOR COMPREHENDING THE NUMBERS USED TO LABEL FIGURES IN THIS REPORT

The "N=" that appears on each graph represents the number of laboratories that reported results. For some graphs, laboratories reported results using more than one test; therefore, the number of results may exceed the actual number of laboratories providing reports. In figures 1-7 and 10, the vertical axis is labeled either as frequency or percentage of results; in figures 8 and 9, this axis is labeled as percentage of reports. However, in all figures, the number appearing directly above or within each bar represents a frequency of results only.

Figure 1. Frequency of HTLV-I/II antibody test result interpretations, by sample type (reactivity), for enzyme immunoassay (EIA), Western blot (WB), and indirect immunofluorescence (IIF), reported by reference laboratories for the October 6, 1997 shipment



* = Indeterminate is not an EIA interpretation option; these areas have been left blank





Figure 2. Percentage of HTLV-I/II reference laboratories, by laboratory type, that reported EIA, WB, and IIF results to the CDC for the October 6, 1997 shipment




Figure 3. Combination of HTLV-I/II antibody tests reported by reference laboratories for the October 6, 1997 shipment




Figure 4. Types of HTLV-I/II antibody test kits used for enzyme immunoassay, Western blot, and indirect immunofluorescence, as reported by reference laboratories to the CDC for the October 6, 1997 shipment










Figure 5. Enzyme immunoassay HTLV-I/II antibody test results, by kit manufacturer, reported by reference laboratories for the October 6, 1997 shipment



Test Result Interpretations

■ Non-Reactive ■ Reactive



Figure 6. Western blot HTLV-I/II antibody test results, by kit manufacturer, reported by reference laboratories for the October 6, 1997 shipment



Test Result Interpretations

- Non-Reactive
- Indeterminate
- Reactive

Figure 7. Indirect immunofluorescence HTLV-I/II antibody test results, by kit manufacturer, reported by reference laboratories for the October 6, 1997 shipment



Test Result Interpretations

■ Non-Reactive ■ Indeterminate ■ Reactive

Figure 8. Western blot HTLV-I/II antibody band patterns reported to CDC by reference laboratories for the October 6, 1997 shipment




Figure 8. Western blot HTLV-I/II antibody band patterns reported to CDC by reference laboratories for the October 6, 1997 shipment




Figure 9. Fluorescence intensity patterns, of HTLV-I/II-infected cells, for IIF results reported to CDC by reference laboratories for the October 6, 1997 shipment




Figure 9. Fluorescence intensity patterns, of HTLV-I/II-infected cells, for IIF results reported to CDC by reference laboratories for the October 6, 1997 shipment




Figure 10. Types of 'Other' HTLV antibody test kits used and results reported by reference laboratories to the CDC for the October 6, 1997 shipment

